

**Summit Corporation plc**  
("Summit plc" or "the Company")

**DIRECTOR SHARE DEALINGS**

**Oxford, UK, 05 March 2010**, Summit (AIM: SUMM), a leading UK drug discovery company with a portfolio of partnered drug programmes and a proprietary second generation iminosugar technology platform, has been notified that Professor Stephen Davies, Non-executive Director and co-founder of the Company, has today purchased 50,000 Ordinary shares of one pence each at a price of 4.69 pence per share.

This purchase is in addition to Professor Davies' purchase of 400,000 Ordinary shares in November 2009 and a subscription for 1,000,000 Ordinary shares as part of the successful fundraising that completed in December 2009.

Professor Davies now holds a total of 7,658,748 shares representing 4.61% of the issued share capital.

- END -

**For more information, please contact:**

**Summit**

Steven Lee, PhD  
Richard Pye, PhD

Tel: +44 (0)1235 443 951

**Singer Capital Markets (Nominated Adviser)**

Shaun Dobson / Claes Spång

Tel: +44 (0)20 3205 7500

**Peckwater PR**

Tarquin Edwards

Tel: +44 (0)7879 458 364

[tarquin.edwards@peckwaterpr.co.uk](mailto:tarquin.edwards@peckwaterpr.co.uk)

**About Summit plc**

Summit is a leading UK based drug discovery company with a portfolio of partnered drug programmes and a major focus on developing new therapeutics from its proprietary second generation iminosugar drug discovery platform.

Summit believes iminosugars are the key to gaining access to several disease mechanisms where classical drug candidates have had little success, and therefore offer a major opportunity for the discovery and development of new medicines.

Carbohydrates play critical roles in maintaining correct function of many normal processes in healthy individuals and provide a wealth of new targets for drug discovery. Iminosugars have the capability of accessing such targets and offer the potential of generating new medicines in a variety of major therapy areas. Summit is currently focussed on metabolic diseases, including diabetes, and infectious diseases.



Summit has a commercial track record of signing programme agreements and currently has a product portfolio comprising of a number of drug programmes with partners including BioMarin Pharmaceuticals, Orient Pharma, Evolva, the Wellcome Trust and the Lilly TB Drug Discovery Initiative. This portfolio requires no further investment from Summit but in the future may generate success based milestone payments of over \$160 million and sales royalties rising to a low teen percentage for the Company.

The company listed on the alternative investment market (AIM) of the London Stock Exchange in October 2004 - symbol: SUMM. Further information about the company is available at [www.summitplc.com](http://www.summitplc.com).